

1 *Article*

2 **Beyond the MEP Pathway: a novel kinase required for prenel utilization**  
3 **by malaria parasites**

4

5 **Marcell Crispim<sup>1,4†</sup>, Ignasi Bofill Verdaguer<sup>1†</sup>, Agustín Hernández<sup>2</sup>, Thales Kronenberger<sup>3</sup>, Àngel**  
6 **Fenollar<sup>4</sup>, María Pía Alberione<sup>4</sup>, Miriam Ramirez<sup>4</sup>, Alejandro Miguel Katzin<sup>1\*</sup>, Luis Izquierdo<sup>4,5\*</sup>**

7

8 <sup>1</sup>Department of Parasitology, Institute of Biomedical Sciences of the University of São Paulo, São Paulo, Brazil.

9 <sup>2</sup>Center for Biological and Health Sciences, Integrated Unit for Research in Biodiversity (BIOTROP-CCBS), Federal University of  
10 São Carlos, São Carlos, Brazil.

11 <sup>3</sup>A) Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tuebingen Center for Academic Drug Discovery, Eberhard Karls  
12 University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany. B) School of Pharmacy, Faculty of Health Sciences,  
13 University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland. C) Excellence Cluster "Controlling Microbes to Fight  
14 Infections" (CMFI), 72076 Tübingen, Germany

15 <sup>4</sup>Barcelona Centre for International Health Research, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.

16 <sup>5</sup>Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain.

17

18 \*Corresponding authors:

19 AMK: Department of Parasitology, Institute of Biomedical Sciences of the University of São Paulo, Av. Lineu Prestes 1374, CEP  
20 05508-000, São Paulo, SP, Brazil. Telephone: +55 11 3091-7330 Fax: 5511 3091-7417. *E-mail address*: amkatzin@icb.usp.br

21 LI: Edifici CEK, Carrer Rosselló 149-153, 08036, Barcelona, Spain. Telephone: +34 932275400 ext. 4276. Fax: +34 93 3129410 *E-*  
22 *mail address*: luis.izquierdo@isglobal.org

23

24 † These authors contributed equally.

25

26 **Abstract**

27 A promising treatment for malaria is a combination of fosmidomycin and clindamycin. Both compounds  
28 inhibit the methylerythritol 4-phosphate (MEP) pathway, the parasitic source of farnesyl and  
29 geranylgeranyl pyrophosphate (FPP and GGPP, respectively). Both FPP and GGPP are crucial for the  
30 biosynthesis of several essential metabolites such as ubiquinone and dolichol, as well as for protein  
31 prenylation. Dietary prenols, such as farnesol (FOH) and geranylgeraniol (GGOH), can rescue parasites  
32 from MEP inhibitors, suggesting the existence of a missing pathway for prenel salvage via phosphorylation,  
33 by competition. In this study, we identified a gene in the genome of *P. falciparum*, encoding a  
34 transmembrane prenel kinase (PolK) involved in the salvage of FOH and GGOH. The enzyme was

35 expressed in *Saccharomyces cerevisiae*, and its FOH/GGOH kinase activities were experimentally  
36 validated. Furthermore, conditional gene knockouts were created to investigate the biological importance  
37 of the FOH/GGOH salvage pathway. The knockout parasites were viable but more susceptible to  
38 fosmidomycin, and their sensitivity to MEP inhibitors could not be rescued by the addition of prenols.  
39 Moreover, the knockout parasites lost their ability to use prenols for protein prenylation. These results  
40 demonstrate that FOH/GGOH salvage is an additional source of isoprenoids by malaria parasites when *de*  
41 *novo* biosynthesis is inhibited. This study also identifies a novel kind of enzyme whose inhibition may  
42 potentiate the antimalarial efficacy of drugs that affect isoprenoid metabolism.

43

44 **Keywords:** Prenol, geranylgeraniol, farnesol, conditional knockout, prenyl-phosphate kinase, *Plasmodium*  
45 *falciparum*, ribosome inhibitors, fosmidomycin, malaria, isoprenoid biosynthesis, protein prenylation.

46

## 47 1. INTRODUCTION

48 *Plasmodium falciparum* causes the most severe form of human malaria, a parasitic disease with a  
49 high global burden. In 2021, the World Health Organization reported an estimated 247 million cases of  
50 malaria and 619,000 malaria-related deaths, with the majority occurring among children and pregnant  
51 women in Sub-Saharan Africa. In 2021, 96% of all malaria-related deaths occurred in this region.  
52 Resistance to current antimalarial drugs is a significant challenge for malaria control, leading to increased  
53 morbidity and mortality (WHO, 2022). Therefore, the identification and development of novel antimalarial  
54 therapies are urgently needed.

55 The most promising targets for the development of antimalarial drugs are those that are unique to  
56 the pathogen and not found in humans. The ancestor of apicomplexan parasites underwent endosymbiosis  
57 with an alga and thus, possess a non-photosynthetic plastid called the apicoplast (Kohler *et al*, 1997) which  
58 contains the targets of some of the current antimalarial drugs in use (Janouskovec *et al*, 2010; Seeber &  
59 Soldati-Favre, 2010). The most extensively studied biological process in the apicoplast is isoprenoid  
60 biosynthesis via the methylerythritol phosphate (MEP) pathway (Figure 1). Unlike animals, which use the  
61 mevalonate (MVA) pathway, the MEP pathway condenses pyruvate and glyceraldehyde 3-phosphate to  
62 produce 5-carbon isoprene units, isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate  
63 (DMAPP). IPP and DMAPP are enzymatically condensed in geranyl pyrophosphate (10 carbon), farnesyl  
64 pyrophosphate (FPP, 15 carbon), and geranylgeranyl pyrophosphate (GGPP, 20 carbon) (Cassera *et al*,  
65 2004; Jordão *et al*, 2011). These metabolites are essential for protein farnesylation and geranylgeranylation  
66 (Figure 1). The parasite also produces longer polyprenyl pyrophosphates for the biosynthesis of ubiquinone-

67 8,9 and dolichols, which are mitochondrial cofactors and lipid carriers for sugar transport in protein  
68 glycosylation, respectively (Gowda & Davidson, 1999; de Macedo *et al*, 2002; Verdaguer *et al*, 2019;  
69 Zimbres *et al*, 2020; Verdaguer *et al*, 2021; Fenollar *et al*, 2022; Okada *et al*, 2022). Isoprenoids produced  
70 by the MEP pathway are thus involved in various essential parasitic processes, such as mitochondrial  
71 activity and post-translational modification of proteins. The antimalarial drug fosmidomycin inhibits the  
72 MEP pathway by targeting the enzyme 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR), which  
73 converts 1-deoxy-D-xylulose 5-phosphate (DXP) to MEP (Figure 1) (Lell *et al*, 2003). Similarly, classic  
74 bacterial ribosome inhibitors (hereafter referred as ribosome inhibitors), such as azithromycin, doxycycline,  
75 or clindamycin, can indirectly inhibit isoprenoid biosynthesis by interfering with apicoplast biogenesis.  
76 Treated parasites transmit defective organelles to their progeny, leading to a delayed death effect in which  
77 the parasites exposed to these drugs cease growth approximately 48 hours after the onset of treatment (Yeh  
78 & DeRisi, 2011; Wu *et al*, 2015; Kennedy *et al*, 2019). Until recently, it was assumed that these drugs  
79 completely inhibited apicoplast formation and all the metabolic processes associated with this organelle.  
80 However, recent studies have found that treatment with ribosome inhibitors leads to the fragmentation of  
81 the apicoplast into vesicles. Whereas these vesicles do not maintain active the MEP pathway, they still  
82 contain other important enzymes (Swift *et al*, 2021).

83 Parasites can be grown indefinitely *in vitro* when exposed to fosmidomycin or ribosome inhibitors  
84 if there is an exogenous source of IPP. Additionally, parasites with impaired isoprenoid biosynthesis can  
85 be partially rescued by the addition of FPP/farnesol (FOH) and GGPP/geranylgeraniol (GGOH), but not  
86 isopentenol, geraniol, octaprenol, nonaprenol or dolichols (Yeh & DeRisi, 2011; Wu *et al*, 2015; Kennedy  
87 *et al*, 2019; Verdaguer *et al*, 2022a). Additional studies characterized the molecular and morphological  
88 phenotype of parasites exposed to ribosome inhibitors in order to investigate their isoprenoid requirements.  
89 Additionally, metabolomic profiling revealed that the lack of ubiquinone and dolichol biosynthesis is not  
90 the primary cause of death, but rather the disruption of the digestive vacuole function (Kennedy *et al*, 2019).  
91 It is now understood that the loss of protein prenylation interferes with vesicular trafficking and ultimately  
92 affects *P. falciparum*'s feeding, leading to their death. In fact, the sort of prenylated proteins in malaria  
93 parasites includes Ras, Rho, and Rap small GTPases, which are involved in cellular signalling and  
94 intracellular trafficking (Suazo *et al*, 2016; Verdaguer *et al*, 2022a). Mechanistically, these processes rely  
95 on transferases that attach FPP or GGPP moieties to the C-terminal cysteine residues of proteins containing  
96 a conserved motif for prenylation, CAAX (C = cysteine, A = aliphatic amino acid, X = diverse terminal  
97 residue) (Farnsworth *et al*, 1990).

98           Several clinical trials using fosmidomycin to treat malaria failed, mostly due to poor antimalarial  
99    efficacy (Fernandes *et al*, 2015). Additionally, the combination of fosmidomycin plus clindamycin was also  
100   unsuccessful in clinics, with no clear evidence of mutations related to its resistance (Lanaspa *et al*, 2012;  
101   Mombo-Ngoma *et al*, 2018). Thus, the failure of these therapies may be due to the intrinsic mechanisms of  
102   the parasite or the pharmacokinetics of fosmidomycin (Guggisberg *et al*, 2016). Therefore, it is crucial to  
103   conduct further research on isoprenoid metabolism in the parasite to develop effective antimalarial  
104   treatments targeting these pathways.


105           An unresolved matter regarding isoprenoid metabolism in *Plasmodium* is related to classic drug-  
106    rescue assays that employ the prenols FOH and GGOH (Zhang *et al*, 2011; Yeh & DeRisi, 2011, Howe *et*  
107    *al*, 2013; Guggisberg *et al* 2014; Kennedy *et al*, 2019; Verdaguer *et al*, 2022a). There is no evidence that  
108    prenyl synthases/transferases would preferably bind prenols, or any other polyprenyl derivative, rather than  
109    polyprenyl-PP. Prenols may orient parallel to the membrane, while polyprenyl pyrophosphates favour a  
110    perpendicular orientation, making their pyrophosphate moieties physically available for interaction with  
111    polyprenyl transferases and synthases (Hartley *et al*, 2013; Nakatani *et al*, 2014; Verdaguer *et al*, 2022b).  
112    Therefore, a FOH/GGOH salvage pathway was proposed to exist, acting via phosphorylation to incorporate  
113    these molecules into the major isoprenoid metabolism (Verdaguer *et al*, 2022b). Our group has previously  
114    characterized the transport of FOH and GGOH in *P. falciparum*, and observed that these prenols are  
115    phosphorylated, condensed into longer isoprenoids, and incorporated into proteins and dolichyl phosphates  
116    (Verdaguer *et al*, 2022a).

117           Prenol phosphorylation has been biochemically demonstrated to occur in membrane extracts of  
118    animal and plant tissues, as well as in archaea (Verdaguer *et al*, 2022b). In 1998, Bentinger *et al*. reported  
119    the first evidence of this pathway in mammals, observing the conversion of FOH to farnesyl monophosphate  
120    (FP) in the 10,000 x g supernatant of rat liver homogenates (Bentinger *et al*, 1998). This FOH kinase activity  
121    was located in rough and smooth microsomes and associated with the inner, luminal surface of the vesicles.  
122    Further analysis identified an activity capable of phosphorylating FP to FPP. Although the biological  
123    function of this pathway remains poorly understood, it is likely to be a mechanism for regulating or  
124    bypassing the isoprenoid biosynthetic pathway, recycling isoprenoids released from prenylated metabolite  
125    degradation, or even facilitating the use of exogenous isoprenoids (Ischebeck *et al*, 2006; Valentin *et al*  
126    2006; Fitzpatrick *et al*, 2011; Vom Dorp *et al*, 2015; Verdaguer *et al*, 2022b). Biochemical evidence suggest  
127    that the pathway is carried out by two separate enzymes: a CTP-dependant prenil kinase (PolK) with  
128    FOH/GGOH kinase activities that produce FP or GGP and a polyprenyl-phosphate kinase. However, only  
129    a few genes encoding these enzymes have been experimentally identified in plants, including the FOLK

130 gene which encodes a FOH kinase in *Arabidopsis thaliana* (Fitzpatrick *et al*, 2011), the VTE5 gene which  
 131 encodes a kinase of phytol (a hydrogenated product of GGOH typical from plants) (Valentin *et al*, 2006),  
 132 and the gene VTE6 which encodes a phytol-P kinase (Vom Dorp *et al*, 2015). The enzymes responsible for  
 133 the salvage pathway of prenols in animals and other organisms remain unidentified. The interest in their  
 134 identification is growing, as recent studies show that prenols can be enzymatically produced by mammal  
 135 phosphatases (Bansal & Vaidya, 1994; Elsabrouty *et al*, 2021) or metabolized from dietary sources, playing  
 136 a role in several diseases (de Wolf *et al*, 2017; Jawad *et al*, 2022). This highlights the potential importance  
 137 of the FOH/GGOH salvage pathway in limiting the efficacy of treatments which target isoprenoid  
 138 metabolism.

139 To address these issues, our efforts focused on identifying the enzymes responsible for the  
 140 FOH/GGOH salvage pathway in *P. falciparum* as a strategy to improve the efficacy of MEP inhibitors. We  
 141 identified a gene in malaria parasites that encodes a PolK, experimentally validated for its FOH/GGOH  
 142 kinase activities. Additionally, using bioinformatics approaches and the creation of conditional gene  
 143 expression knockout parasites, we sought to understand the biological significance of the FOH/GGOH  
 144 salvage pathway in malaria parasites. Our findings provide important insights into the isoprenoid  
 145 metabolism of malaria parasites, and the potential of targeting the FOH/GGOH salvage pathway to improve  
 146 the efficacy of antimalarial drugs.

147  
 148



149

150

151 **Figure 1. Isoprenoid sources and distribution in malaria parasites.** The figure illustrates the sources and distribution  
 152 of isoprenoids in malaria parasites. The figure includes the biosynthesis of isoprenoids via the MEP pathway, starting  
 153 with the condensation of glyceraldehyde-3-phosphate (G3P) and pyruvate, and leads to the formation of isopentenyl

154 pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), and their subsequent condensation to form geranyl  
155 pyrophosphate (GPP), farnesyl pyrophosphate (FPP), and geranylgeranyl pyrophosphate (GGPP). These longer  
156 isoprenoids are essential for the biosynthesis of ubiquinone, dolichol, and for protein prenylation. The figure also shows  
157 the targets of fosmidomycin and ribosome inhibitors in the parasite. The chemical structures of FOH and GGOH are  
158 represented.

159

## 160 **2. RESULTS**

### 161 **2.1 Candidates for apicomplexan prenyl kinases are homologous to their plant/algae counterparts** 162 **and belong to a diverse family with multiple gene duplications.**

163 We recently demonstrated the ability of parasites to phosphorylate FOH and GGOH (Verdaguer *et al*  
164 2022a). Hence, we started a bioinformatic search for gene candidates to encode a kinase of prenyls. As  
165 seeds, we used the *A. thaliana* and *Synechocystis* spp. (strain PCC 6803 / Kazusa) VTE5 proteins (phytol  
166 kinase) and *A. thaliana* FOLK protein (farnesol kinase) since their enzymatic activity was already described  
167 in the literature (Q9LZ76 and P74653 entries in UniProt, respectively) (Valentin *et al*, 2006; Fitzpatrick *et*  
168 *al*, 2011). Both sequences were defined as control representatives and were used as queries to a survey for  
169 homologous sequences in the *P. falciparum* genome in the PlasmoDB database (<https://plasmodb.org/>).  
170 Sequence homology searches were performed using the BlastP algorithm against the protein database of all  
171 *Plasmodium* species available (Supporting information, Figure S3). As a result, only two possible  
172 orthologous proteins were obtained in *Plasmodium yoelli* genome (PY17X\_1224100 and  
173 PYYM\_1223600). The ortholog of these genes in *P. falciparum* 3D7 and NF54 strains were further  
174 identified (PF3D7\_0710300 and PfNF54\_070015200, with 100% identity between them) and used in  
175 multiple alignments with the control representative sequences and other four sequences with putative  
176 annotation for phytol kinase (Supporting information, Figure S2). PfNF54\_070015200 has 11%, 15% and  
177 10% similarity with *A. thaliana* VTE5, *Synechocystis* spp. VTE5, and *A. thaliana* FOLK protein,  
178 respectively. Phylogenetic analysis of the retrieved representative prenyl binding proteins (Figure 2A and  
179 supporting information Figure S3) display several diverse clades with multiple gene duplications. We  
180 discuss five groups, highlighted by coloured boxes in Figure 2A, as follows: a root-external group  
181 containing dolichol kinase (DolK) enzymes which are members of the Polyprenol kinase family  
182 (InterproScan num. IPR032974; orange, see also Supporting information, Figure S4); phytol/FOH kinases  
183 from plants and unicellular algae (PhyK and Folk, respectively, in green, yellow, and cyan); a  
184 *Chlamydomonas reinhardtii* clade (A0XX\_CHLRE, where A0XX is a generic label for all the sequences  
185 from *C. reinhardtii*'s taxa representing different genes) from which specific Apicomplexa monophyletic


186 clade is derived (in red, Supporting information Figure S4). This supports the idea that *Plasmodium*'s PolK  
187 is more similar to unicellular algae proteins, which is consistent with the endosymbiosis event that occurred  
188 in apicomplexan ancestors.

189

190 We assessed the potential of an AlphaFold-derived structural model of the putative *Pf*PolK to bind prenyls  
191 using a combination of docking and long Molecular Dynamics (MD) simulations. The generated model  
192 displays eight conserved transmembrane helices (TM1-8, Figure 2B), a conserved CTP binding pocket and  
193 a potential prenyl binding pocket (in grey). The CTP binding pocket ends in the charged clamp motif  
194 (Arg29, Lys30 and His33), whose positive charges could be used to orient substrate phosphates into the  
195 catalytic conformation, while the nucleotide ring is stabilized by a conserved “hinge” region composed by  
196 the main chain of Thr144 and the side chain of Glu179 (Figure 2B, down inset). Meanwhile, the potential  
197 prenyl binding pocket, composed by the TM's 1 – 4, can accommodate both FOH (Figure 2C) and GGOH  
198 (Figure 2D) relying on the conformational change, upon simulation, of the Phe43 and Ile71 to fit the later.  
199 The hydroxyl group of both substrates coordinates the Arg-Lys-His triad by conserved water interactions.  
200 The MD trajectories were further utilized to infer the substrates predicted binding energy (Figure 2E),  
201 suggesting that GGOH (-19.1 kcal/mol) would have a lower potential binding energy, when compared to  
202 the FOH (-16.5 kcal/mol), with both substrates being able to bind *Pf*PolK.

203

204



205


206 **Figure 2. *Pf*PolK phylogenetic analysis and structural model.** A) Overall phylogenetic dendrogram of prenil  
 207 binding proteins generated using maximum likelihood method (see Methods). Branch support values (Bayes posterior  
 208 probability) are displayed as numbers for the most relevant clade separation, as well as colours (from the highest scores,  
 209 in blue, to the lowest values, in red) and thickness of the branches. The five discussed groups are highlighted by  
 210 coloured boxes as follows: root-external group of DolK (orange), phytol/FOH kinases from plants and unicellular algae  
 211 (PhyK and Folk, respectively, in green, yellow, and cyan) and the *C. reinhardtii* (A0XX\_CHLRE, where A0XX is a  
 212 generic label for all the *C. reinhardtii*'s taxa) clade from which a specific Apicomplexa monophyletic clade arises (in  
 213 red). Supporting information provides the full phylogenetic tree with all values for branch support and labelled taxa, as  
 214 well as a key-taxa conversion table. B) AlphaFold 2 *Pf*PolK model displays eight conserved transmembrane helices  
 215 (TM1-8, coloured) and a potential prenil binding pocket, depicting in the bottom the nucleotide-binding site with the  
 216 Thr144 and Glu179 composing a hinge region. This model was used to generate the potential binding mode for FOH

217 (green, C) and GGOH (blue, D) by a combination of flexible docking and long molecular dynamics simulations (5x1  $\mu$ s  
 218 for each system in explicit solvent and membrane). E) the MD trajectories were utilized to infer the substrates predicted  
 219 binding energy (Kcal/mol.HAC, where HAC – heavy atom count), suggesting from the median values of the violin-  
 220 plot displayed distribution that GGOH would have a lower potential binding energy. Dotted lines describe the first  
 221 quartile amplitude.

222

## 223 2.2 Farnesol/geranylgeraniol kinase activity of *Pf*PolK

224 To study the catalytic activity of *Pf*PolK candidate, we expressed its gene heterologously in yeast. This  
 225 expression system was chosen due to its advantages as a eukaryotic protein-expression system, and because  
 226 it was previously demonstrated that this organism did not phosphorylate FOH and GGOH (Fitzpatrick *et*  
 227 *al.*, 2011). Therefore, the W303-1A strain of *S. cerevisiae* was transformed with p416-GPD vector (empty  
 228 vector employed, as a control) or engineered to express *Pf*PolK from p416-*Pf*PolK plasmid. Transformant  
 229 yeasts were grown in SD- an uracil drop-out medium and employed for enzymatic assays. The incubation  
 230 of yeast extracts with [<sup>3</sup>H] FOH or [<sup>3</sup>H] GGOH plus CTP produced radiolabeled compounds  
 231 chromatographically compatible with their respective phosphates (Rf ~0.5). The formation of polyprenyl  
 232 phosphates was not observed in assays without the addition of CTP or employing wild-type yeasts  
 233 transformed with the empty vector (Figure 3). No compounds displaying chromatographic compatibility  
 234 with FPP and GGPP were detected. Although we used the same amounts of substrates in all assays, the  
 235 chromatographic spots compatible with FOH and FP were more visible than those compatible with GGOH  
 236 and GGP. This issue is likely caused by varying extraction efficiencies between different prenyls.



237

238 **Figure 3. Farnesol and geranylgeraniol kinase activities.** Autoradiographies of the PolK enzymatic activity assays  
 239 using [<sup>3</sup>H] FOH or [<sup>3</sup>H] GGOH as substrates and chromatographed by TLC. The enzyme source of these assays came

240 from whole extracts of yeast strains transformed with either the empty vector (p416-GPD) or p416-*Pf*PolK. Compounds  
241 added to the enzymatic reaction are indicated under the TLC autoradiography image. The retention of different  
242 standards is also indicated. These experiments were repeated three times with similar results.

243


### 244 **2.3 Conditional knockout uncovers the relationship between *Pf*PolK and MEP inhibitors.**

245 After confirming the catalytic activity of *Pf*PolK, we investigated its biological importance in malaria  
246 parasites by generating conditional knockout NF54 parasites for PfNF54\_070015200 (Figures 4A and 4B).  
247 Clones PolK-loxP-C3, E3, and G9 were obtained and genomic integration was confirmed by PCR (Figure  
248 4C). Expected excision of the floxed *Pf*PolK-loxP was also confirmed by PCR 24, 48, 96 and 144 h after  
249 knockout induction with rapamycin, generating  $\Delta$ -PolK parasite lines (Figure 4D). Importantly,  $\Delta$ -PolK  
250 parasites showed no reduction in growth and could be maintained indefinitely in culture, as demonstrated  
251 by monitoring their growth for up to 144 hours (Figure 4E). Western blots revealed that transfected parasites  
252 had an HA epitope fused to a ~31 kDa protein, matching the expected size of the PolK protein. In contrast,  
253 HA-tagged PolK protein was not detectable in  $\Delta$ -PolK parasites 48 hours after induction of *Pf*PolK-loxP  
254 excision with rapamycin (Figure 4F; see original images in supporting information, Figure S5).  
255 Immunofluorescence assays also revealed that the HA-tagged protein did not exclusively co-localize with  
256 the apicoplast (Figure 4G), suggesting that the prenel salvage pathway could be at least partially, apicoplast-  
257 independent.

258 The susceptibility of these parasites to MEP inhibitors was studied next. Loss of the PolK gene increased  
259 the sensitivity of mutant parasites to fosmidomycin two-fold, when compared to wild type parasites ( $IC_{50}$   
260 fosmidomycin  $1.09 \pm 0.33 \mu\text{M}$  vs  $0.51 \pm 0.07 \mu\text{M}$ ) (Figure 5A, B). No significant differences were observed  
261 in the effect of clindamycin under the same conditions, possibly due wider effects on parasites metabolism.  
262 As expected, the presence of prenel, FOH or GGOH, in the medium of control parasites reduced their  
263 sensitivity to fosmidomycin. This was evidenced by a 3-fold increase in the  $IC_{50}$  for fosmidomycin in the  
264 presence of FOH, and a 15-fold increase in the presence of GGOH, when compared to controls growth  
265 without prenel supplementation. Likewise, the  $IC_{50}$  for clindamycin increased 5-fold in the presence of  
266 GGOH, as compared to the control group with no-additions (Figure 5C, D). Remarkably, the addition of  
267 prenel did not have any rescue effects on the antimalarial activity of fosmidomycin or clindamycin in  $\Delta$ -  
268 PolK parasites (see Figure 5A-D). This strongly suggests that the presence of PolK is necessary for the  
269 rescue effect of prenel on the antimalarial activity of MEP inhibitors.

270





271



273 **Figure 4. Conditional knockout of *P. falciparum* PolK gene.** (A) Diagram depicting the edition of single-exon gene  
274 *P. falciparum* PolK. Using Cas9-assisted genome editing, all 612 bp of the native *Pf*PolK (WT) open reading frame  
275 were replaced by a recodonized sequence (*Pf*PolK recod) and a 3x-HA sequence (yellow box) in the 5' end of the  
276 sequence and all flanked by two loxP sites (orange boxes). The position of the 20-nucleotide region targeted by the  
277 single guide RNA (sgRNA) is indicated (purple box). (B) Diagram of the rapamycin-induced site-specific excision.  
278 Recombination between the loxP sites removes the entire recodonized gene (green box) and 3-HA sequence; (C) PCR  
279 assessment of the genome integration of the construct in the *Pf*PolK locus. Wild type (NF54 DiCre control) was  
280 confirmed using Polk-WT-forward and reverse primers. Using PolK-recod-forward and reverse primers it was detected  
281 redoconized version of PolK in transgenic parasites (Clones E3, C3 and G9) and in a plasmid containing the  
282 recodonized PolK (pUC19 polk recod). (D) Confirmation of the rapamycin-induced *Pf*PolK gene excision in the clone  
283 PolK-loxP E3. The deletion was confirmed by PCR 24, 48, 96 and 144 h after treatment with DMSO (D) or rapamycin  
284 (R) using primers polk-HR1-forward and polk-HR2-reverse (in red and blue on panel B, respectively). Excision reduces  
285 the amplicon from 1840 bp to 799 bp, disrupting *Pf*PolK. (E) Figure shows the 144h evolution of parasitemia in  
286 different clones in which *Pf*PolK gene was excised (parasites exposed to rapamycin) or not (parasites exposed to  
287 DMSO). All the graphs represent the mean and SD of at least three experiments. (F) Western blot of transgenic parasites  
288 (left) and the respective Comassie stained gel (right). Western blot was performed to analyse the HA-tagged *Pf*PolK of  
289 parasites in which *Pf*PolK was excised (lane 1, parasites exposed to rapamycin) or preserved (lane 2, parasites exposed  
290 to DMSO). (G) Immunofluorescence analysis of HA-tagged *Pf*PolK of parasites in which *Pf*PolK was excised (parasites  
291 exposed to rapamycin,  $\Delta$ -Polk) or not (control parasites, exposed to DMSO). HA-tagged *Pf*PolK is marked in red, the  
292 apicoplast is green and the nucleus in blue.

293

294




296 **Figure 5. Phenotypic characterization of knockout parasites.** (A) Fosmidomycin dose-response curves after 48h of  
297 parasites maintaining a functional *Pf*PolK (DMSO (Vehicle/control)) or  $\Delta$ -PolK parasites. These parasites were  
298 cultured in RPMI medium in the presence or absence of the indicated prenyls (5  $\mu$ M). (B) Fosmidomycin IC<sub>50</sub> values  
299 of the results exposed in the previous panel. (C) Clindamycin dose-response curves after 96 h parasites maintaining a  
300 functional *Pf*PolK (DMSO (Vehicle/control)) or  $\Delta$ -PolK parasites. These parasites were cultured in RPMI medium in  
301 the presence or absence of GGOH (5  $\mu$ M), as indicated. (D) Clindamycin IC<sub>50</sub> values of the results exposed in the  
302 previous panel. Statistical analysis was made using one-way ANOVA/Dunnet's Multiple Comparison Test. \*p<0.05,  
303 \*\*p<0.01, \*\*\*p<0.001. Comparison made to Vehicle/Control data. Error bars represent standard deviation (n = 3).

304

#### 305 **2.4 Farnesol and geranylgeraniol phosphorylation is required for their utilization for protein** 306 **prenylation.**

307 As mentioned above, lack of protein prenylation disrupts the function of the digestive vacuole and leads to  
308 the loss of parasitic homeostasis (Kennedy et al., 2019). To understand the effects of PolK deletion on FOH  
309 utilization, the incorporation of [<sup>3</sup>H] FOH and [<sup>3</sup>H] isoleucine (control) into proteins was determined in  
310 parasites with functional *Pf*PolK and after the excision of the gene (Figure 6). The deletion of *Pf*PolK  
311 resulted in a significant decrease in counts per minute (CPM) corresponding to [<sup>3</sup>H] FOH-labeled proteins  
312 compared to parasites with an intact PolK enzyme. Only a few counts were still detected in  $\Delta$ -PolK  
313 parasites, likely corresponding to the remaining dolichol-P oligosaccharide and/or other radiolabeled lipids  
314 that were not covalently bound to proteins. It is worth noting that all parasites incorporated similar levels  
315 of [<sup>3</sup>H] isoleucine into proteins, indicating no observable defects in protein synthesis other than prenylation.



316

317 **Figure 6. Farnesol and isoleucine incorporation into proteins in  $\Delta$ -PolK parasites.** The graph shows the levels of  
318 incorporation of <sup>3</sup>H-FOH and <sup>3</sup>H-isoleucine (<sup>3</sup>H-Ile) into TCA-precipitated proteins in parasites maintaining or not a  
319 functional *Pf*PolK. Statistical analysis was made using one-way ANOVA One-way ANOVA / Tukey's Multiple

320 Comparison Test.\*p<0.05, \*\*p<0.01, \*\*\*p<0.001. Comparison made to between samples of parasites exposed to the  
321 same radiolabelled precursor but maintaining or not *Pf*PolK. Error bars represent standard deviation (n = 3).

322

### 323 3. DISCUSSION

324 Malaria parasites can grow indefinitely in the presence of fosmidomycin or ribosome inhibitors if  
325 exogenous IPP is added to the culture medium (Yeh & DeRisi, 2011). Moreover, pharmacologically-  
326 induced isoprenoid biosynthesis deficiency can be transiently mitigated by the addition of FOH, GGOH  
327 and unsaponifiable lipids from food, such as sunflower oil and arugula (Yeh & DeRisi, 2011; Wu *et al*,  
328 2015; Kennedy *et al*, 2019; Verdaguer *et al*, 2022a). In a recent study, our group showed that radiolabelled  
329 FOH and GGOH can be incorporated into various long-chain prenols (>20C in length), dolichols, and  
330 proteins (Verdaguer *et al*, 2022a). However, since all characterized polyprenyl transferases and synthases  
331 use polyprenyl pyrophosphates as their natural substrates, and there is no evidence that these enzymes can  
332 use prenols, a phosphorylation pathway for FOH and GGOH salvage is required in malaria parasites.  
333 Therefore, we hypothesized the existence of a phosphorylation pathway for FOH and GGOH salvage in  
334 malaria parasites and, remarkably, we recently described that *P. falciparum* phosphorylate [<sup>3</sup>H] FOH and  
335 [<sup>3</sup>H] GGOH into their pyrophosphate counterparts. These results significantly support the existence of a  
336 plasmodial FOH/GGOH salvage pathway (Verdaguer *et al* 2022a). In photosynthetic organisms the  
337 phosphorylation of FOH and GGOH is carried out by two separate enzymes: a prenol kinase and a  
338 polyprenyl-phosphate kinase (Verdaguer *et al* 2022a). In photosynthetic organisms the phosphorylation of  
339 FOH and GGOH is carried out by two separate enzymes: a prenol kinase and a polyprenyl-phosphate kinase  
340 (Verdaguer *et al* 2022b). However, only a few genes have been unequivocally identified to encode those  
341 enzymes (Valentin *et al* 2006; Fitzpatrick *et al*, 2011; Vom Dorp *et al*, 2015). Despite the scarce literature  
342 on prenol kinases, we were able to identify a candidate for PolK in *P. falciparum* through BLAST analysis.  
343 This enzyme was heterologously expressed in *S. cerevisiae* and its FOH and GGOH kinase activity was  
344 biochemically confirmed. Remarkably, *Pf*PolK only catalyses lipid mono-phosphorylations, although it can  
345 use either FOH or GGOH as lipid substrates. Consequently, the parasite probably possesses at least another  
346 enzyme with polyprenyl-P kinase activity to make prenols available for further use. The low sequence  
347 similarity shared by these enzymes is probably the reason for not finding it in the initial searches.

348 The results here presented could represent a significant contribution to the field of isoprenoid  
349 metabolism, as it links the plasmodial prenol kinase function to a new class of enzymes in nature.  
350 Remarkably, this is the first FOH/GGOH kinase enzyme discovered in a non-photosynthetic organism. As  
351 observed in the phylogenetic analysis, putative prenol kinases comprise a very divergent group of clades,

352 including the group of DolK, phytol/FOH kinases from plants and unicellular algae, and a *C. reinhardtii*  
353 clade, from which a specific Apicomplexa monophyletic clade is derived. This finding supports the idea  
354 that *Plasmodium*'s PolK is more similar to unicellular algae proteins, consistent with the endosymbiosis  
355 event that occurred in apicomplexan ancestors. Also, the paucity of verified enzymes in all commented  
356 clades open the possibility to assign pyrophosphorylating activity to some of these putative enzymes. The  
357 model provided structural insights into *Pf*PolK, revealing eight conserved transmembrane helices and a  
358 conserved CTP binding pocket that could be used to orient the phosphates into the catalytic conformation.  
359 Additionally, the nucleotide ring is stabilized by a conserved hinge region. The model also uncovered a  
360 novel prenil binding pocket composed of TM's 1-4, capable to accommodate both FOH and GGOH.

361 After *Pf*PolK identification, we studied the biological relevance of the FOH/GGOH salvage  
362 pathway. *Pf*PolK appears to be expressed throughout all stages of asexual intraerythrocytic development  
363 (Chappell *et al*, 2020), highlighting its potential importance in the parasite's lifecycle. Previous studies  
364 indicated that the gene is essential in *P. falciparum* (Zhang *et al*, 2018), whereas studies in rodent malaria  
365 parasites predicted it to be dispensable (Bushell *et al*, 2017). Interestingly,  $\Delta$ -PolK parasites remained fully  
366 viable with no observable growth rate changes, in agreement with the observations made in rodent parasites.  
367 These results suggest that while the FOH/GGOH salvage pathway may be an important alternative source  
368 of isoprenoids, it is not essential for parasite survival, probably due to the endogenous biosynthesis of  
369 isoprenoids via the MEP pathway. IFAs revealed that *Pf*PolK did not exclusively co-localizes with the  
370 apicoplast marker (Figure 4G), suggesting that the prenil salvage pathway is at least partially, apicoplast-  
371 independent. This contradicts previous large-scale studies which target this protein to the apicoplast  
372 (Boucher *et al*, 2018). In line with our findings, bioinformatic deep learning signal prediction indicates that  
373 this enzyme is localized in the endoplasmic reticulum of malaria parasites (Thumuluri *et al*, 2022). In fact,  
374 other studies indicate that the majority of prenil kinase activities in animals and bacteria are located in the  
375 approximately 10,000 x g supernatant of tissue homogenates, rough and smooth microsomes, and  
376 associated with the inner, luminal surface of the vesicles (Verdaguer *et al*, 2022b).

377  $\Delta$ -PolK parasites could not be rescued from the antimalarial effects of fosmidomycin or clindamycin by the  
378 addition of FOH or GGOH. As far as we know, this observation is the first evidence of FOH and GGOH  
379 phosphorylation as a mandatory step for their utilization by living organisms, highlighting the biological  
380 relevance of the FOH/GGOH salvage pathway particularly when *de novo* isoprenoid biosynthesis is  
381 inhibited. The biological relevance of the FOH/GGOH salvage pathway in *P. falciparum* raises important  
382 questions. In our view, this pathway could serve as an alternative source of isoprenoids for the parasite,  
383 independent of the Apicoplast. Furthermore, the pathway could be important for recycling prenils released

384 from the degradation of endogenous prenylated metabolites. This mechanism is similar to the preno-  
385 salvage pathway in plants, which also recycles prenols from chlorophyll degradation (Ischebeck *et al*, 2006;  
386 Valentin *et al* 2006). In addition, *P. falciparum* FOH/GGOH salvage pathway in the parasite may serves as  
387 a mechanism to scavenge FOH and GGOH derived from the host. Thus, preno- scavenging could help the  
388 parasite optimize its energy usage for isoprenoid biosynthesis and partially complement its metabolic  
389 requirements. Remarkably, the fact that these nutrients can reduce the efficacy of MEP inhibitors *in vitro*  
390 suggests the potential importance of this pathway in limiting the effectiveness of this type of antimalarial  
391 drug in clinical settings (Verdaguer *et al*, 2022a). Contrarily to this hypothesis, other authors previously  
392 concluded that the parasite may rely exclusively on endogenous isoprenoid biosynthesis based on the  
393 observation that increasing concentrations of human plasma components in culture did not affect the  
394 antimalarial effect of fosmidomycin (Yeh & DeRisi, 2011). However, it is important to note that the  
395 concentration of prenols in blood and the physiology of their absorption/excretion in humans remain largely  
396 unknown (based on data from the Human Metabolome Database site, <http://www.hmdb.ca/>). Thus, further  
397 research is needed to assess if the FOH/GGOH salvage pathway naturally scavenges host prenols during  
398 parasite infections and to determine whether this phenomenon could be related to the limited efficacy of  
399 fosmidomycin in clinical trials. The identification of *Pf*PolK opens up new avenues for these studies to be  
400 conducted, and may ultimately lead to the development of novel strategies for combatting malaria.  
401 Noteworthy,  $\Delta$ -PolK parasites showed to be slightly more susceptible to fosmidomycin. In our point of view,  
402 this observation may be a consequence of the presence of small amounts of FOH and/or GGOH in the *in*  
403 *vitro* culture system, may be coming from the bovine components or human red blood cells (note that no  
404 data is available about FOH/GGOH quantification in blood or commercial serum substitutes). While this  
405 source may not be sufficient to supply the parasite's isoprenoid requirements *in vitro* under normal culture  
406 conditions, it may still contribute to some extent to the observed effects of fosmidomycin *in vitro* tests.

407 Besides malaria, the dietary consumption of GGOH found in foods like vegetable oils has already  
408 been shown to have implications for cancer therapy. Studies reveal that dietary GGOH limits the efficacy  
409 of statins, commonly used inhibitors of the mevalonate pathway, in treating certain types of cancers.  
410 Specifically, GGOH-rich foods can block statin-induced regression of ovarian tumour xenografts in mice.  
411 These findings show that dietary prenols are metabolized and have a significant impact on the outcome of  
412 clinical trials for cancer therapies (de Wolf *et al*, 2017; Prior *et al*, 2012; Healy *et al*, 2022). The use of  
413 isoprenoid biosynthesis inhibitors has also been explored in other MEP pathway-dependent pathogens such  
414 as *Toxoplasma* (Nair *et al*, 2011), *Babesia* (Wang *et al*, 2020), and *Mycobacterium tuberculosis* (Brown &  
415 Parish, 2008), as well as in MVA pathway-dependent parasites such as *Leishmania* (Dinesh *et al* 2014).

416 Importantly, most of these pathogens can also be rescued from fosmidomycin by FOH and GGOH (Zhang  
417 *et al*, 2011; Li *et al*, 2013; He *et al*, 2018; Kennedy *et al*, 2019; Wang *et al* 2020) and thus, possibly possess  
418 an active prenyl salvage pathway. To date, isoprenoid biosynthesis inhibitors have only been used in clinical  
419 settings for their cholesterol-lowering effects (e.g. simvastatin) and to prevent bone resorption in  
420 osteoporosis (e.g. FPP synthase inhibitors such as bisphosphonates) (Verdaguer *et al*, 2022b). However,  
421 available data suggest that these inhibitors might have potential in the treatment of several infectious  
422 diseases and cancer. The identification and characterization of *PfPolK* as an enzyme critical for the  
423 FOH/GGOH salvage pathway not only provide new insights into the mechanisms underlying malaria  
424 parasite metabolism, but also opens new avenues for the utilization and improvement of antimalarial  
425 therapies currently under study.

426

#### 427 **4. CONCLUSIONS**

428 The focus of this work was the identification of the enzymes responsible for the salvage pathway of FOH  
429 and GGOH in the parasite and their relationship with MEP-targeting drugs. As a result, we identified  
430 *PfPolK*, a novel lipid kinase. Through biochemical and molecular approaches, the catalytic activity and  
431 biological importance of this transmembrane enzyme were characterized. Our data revealed the non-  
432 essential role of *PfPolK* in parasite survival and its crucial involvement in the use of exogenous prenyls for  
433 protein prenylation. *PfPolK* is also key for maintaining cell homeostasis under the effects of MEP  
434 inhibitors. Indeed, we think the findings of this study are not only relevant to understand the fascinating  
435 metabolism of malaria parasites, but also to provide new insights into the evolution of the isoprenoid  
436 metabolism, and possibly to for the development of novel therapeutic strategies in the treatment of other  
437 diseases.

438

#### 439 **5. MATERIALS AND METHODS**

##### 440 **5.1 Reagents, stock solutions and parasitic strains**

441 AlbuMAX™ II Lipid-Rich BSA and RPMI-1640 were purchased from Thermo Fisher Scientific®  
442 (Leicestershire, UK). Dolichol and dolichyl-P 13-21 were purchased from Avanti® (Alabama, USA). [1-  
443 (n)-<sup>3</sup>H] GGOH (14 Ci/mmol; 1 mCi/mL), [1-(n)-<sup>3</sup>H] FOH (14 Ci/mmol; 1mCi/mL) and L-[4,5-<sup>3</sup>H(N)]  
444 isoleucine (30-60 Ci/mmol; 1 mCi/ml) were purchased from American Radiolabeled Chemicals® (St. Louis,  
445 USA). SYBR Green I® nucleic acid gel stain and SYTO® 11 were purchased from Thermo Fisher  
446 Scientific® (Waltham, Massachusetts, EUA). Sterile stock solutions were prepared at 10 mM for  
447 fosmidomycin sodium salt hydrate in water, 2 mM clindamycin hydrochloride in water, 125 mM of GGOH

448 in ethanol and 200 mM of each other non-radiolabelled prenols in ethanol. All other reagents were  
449 purchased from Sigma® (St. Louis, Missouri USA) or specific companies, as cited in the text. Polyprenyl  
450 phosphates were obtained by mild acid treatment of the respective commercial pyrophosphates (Sigma)  
451 (Ohnuma *et al*, 1996). For this work, a Cre-LoxP *P. falciparum* NF54 strain (Tibúrcio *et al.*, 2019), a  
452 generous gift of Moritz Treeck (The Francis Crick Institute, London, United Kingdom), was employed.

453

#### 454 **5.2 *P. falciparum* in vitro culture and synchronization**

455 *P. falciparum* NF54 DiCre cells were cultured *in vitro* following the Trager and Jensen culture method  
456 employing RPMI-1640 medium completed with 0.5% AlbuMAX™ II Lipid-Rich BSA. Parasites were  
457 maintained in 75 cm<sup>2</sup> cell culture flasks at 37 °C (Trager & Jensen, 1976; Radfar *et al*, 2009; Crispim *et al*,  
458 2022). The culture medium pH was adjusted to 7.4 and was introduced a gas mixture of 5% CO<sub>2</sub>, 5% O<sub>2</sub>  
459 and 90% N<sub>2</sub> purchased from Air Products Brasil LTDA® (São Paulo, SP, Brazil). Parasite synchronization  
460 at ring stage was performed with 5% (w/v) D-sorbitol solution as described previously (Lambros &  
461 Vanderberg, 1979). Parasite development was monitored microscopically on Giemsa-stained smears. PCR  
462 for mycoplasma and optic microscopy were used to monitor culture contamination (Rowe *et al*, 1998)

463

#### 464 **5.3 Metabolic labelling of parasites**

465 Our work focused on biochemical experiments in schizont stages because of previous studies showing a  
466 higher incorporation rate of [<sup>3</sup>H] isoprenic moieties at this stage (Kimura *et al*, 2011). For this, synchronous  
467 cultures of *P. falciparum* at the ring stage in 25 cm<sup>2</sup> flasks were labelled with either 0.75 µCi/ml [<sup>3</sup>H] FOH  
468 or 40 µCi/ml [<sup>3</sup>H] isoleucine employed as control of protein synthesis (Martin & Kirk, 2007). After 12–16  
469 h, parasites at trophozoite/schizont stages were obtained by saponin lysis (Christopher & Fulton, 1939). For  
470 this, cultures pellets were lysed with 30 mL 0.03 % saponin in PBS at 4 °C. Parasites were then centrifuged  
471 at 1,500 *x g* for 5 min at 4 °C and subsequently washed in PBS.

472

#### 473 **5.4 Assessment of radiolabelled proteins**

474 The assessment of radiolabeled proteins was performed following a similar protocol as described elsewhere  
475 (Buesing & Gessner, 2003). Radiolabeled parasites were suspended in 100 µL of lysis buffer (2% w/v SDS,  
476 60 mM DTT in 40 mM Tris-Base pH 9). The samples were then cooled at room temperature, and proteins  
477 were precipitated by adding 20% trichloroacetic acid (TCA) in acetone at 4 °C. The samples were kept on  
478 ice for 5 minutes, and the proteins were collected by centrifugation at 12,000 *x g* for 10 minutes. The  
479 precipitate was washed three times with 80% acetone. Subsequently, the proteins were dissolved by

480 incubating them at 90 °C in alkaline buffer (0.5 M NaOH, 25 mM EDTA, 0.1 w/v SDS in water) for 30  
481 minutes. Finally, 1 mL of liquid scintillation mixture (PerkinElmer Life Sciences, MA, USA) was added to  
482 the samples. After vortex, the radioactivity of samples was measured using a Beckman LS 5000 TD  $\beta$ -  
483 counter apparatus (Beckman, CA, USA) and results were analysed using GraphPad Prism® software.

484

## 485 **5.5 Drug-rescue assays in malaria parasites.**

486 In some cases, it was calculated the dose–response curve and the concentration of drug/metabolite required  
487 to cause a 50% reduction in parasite growth (IC<sub>50</sub> value). Assays started at the ring stage at 1% or 0.15%  
488 parasitemia and had a duration of 48 h or 96h. Serial dilutions of the antimalarials were prepared in 96-well  
489 microplates in RPMI complete medium supplemented or not with FOH / GGOH. Solvent controls and  
490 untreated controls were always included and results were analysed by GraphPad Prism® software. All  
491 experiments which monitor parasitic growth were performed at least three times with three or four technical  
492 replicates. Parasitemia was monitored by flow cytometry using the nucleic acid stain SYTO 11 (0.016  $\mu$ M)  
493 (Life Technologies no. S7573) in a BD LSRFortessa machine as previously described (Portugaliza *et al.*,  
494 2019) or in a BD FACSCalibur machine as previously described (Rovira-Graells *et al.*, 2016). The data  
495 was adjusted to a dose–response curve to determine the IC<sub>50</sub> value.

496

## 497 **5.6 Bioinformatics**

### 498 **5.6.1 Sequence similarity search and phylogenetic tree**

499 Sequences from model organisms were retrieved from UniProt, using the term ‘prenol kinase’ as the  
500 keyword. Sequences were retrieved from NCBI/GenBank using the Blast tool (with scoring matrix  
501 BLOSUM45 for distant similar sequences) with an e-value cut-off of 10<sup>-5</sup> creating a dataset. Additionally,  
502 no similar sequences were found in vertebrate genomes. Sequence renaming and editing were performed  
503 with in-house Perl scripts. Sequences with less than 30% global similarity or missing the ORF initiation  
504 codon were excluded from further analyses. The full dataset was clustered by similarity (70%) using CD-  
505 Hit (Huang *et al.*, 2010) and a set of representative sequences were selected for global alignment using  
506 Muscle (Edgar, 2004). This algorithm often selects single organisms representing a full clade of highly  
507 similar sequences, randomly selecting a centroid sequence within the cluster as a representative.  
508 Maximum likelihood phylogenetic tree was generated using PhyML 3.0 (Guindon *et al.*, 2010), with  
509 posterior probability values (aBayes) as branch statistical support. The substitution model JTT was selected  
510 for calculations, by ProtTest3 (Darriba *et al.*, 2011), based on the highest Bayesian Information Criterion  
511 values. All other parameters, except the equilibrium frequencies, were estimated from the dataset.

512 Dendrogram figures were generated using FigTree 1.4.4 (see <http://tree.bio.ed.ac.uk/software/figtree/>), last  
513 access in April 2023).

514

### 515 **5.6.2 Alphafold model and molecular docking**

516 *Pf*PolK model was retrieved from AlphaFold database (sequence: PF3D7\_0710300,  
517 <https://alphafold.ebi.ac.uk/entry/C0H4M5>) and prepared using the PrepWizard implemented in Maestro  
518 2022v4 with standard options. All substrate ligands for docking were drawn using Maestro and prepared  
519 using LigPrep to generate the three-dimensional conformation, adjust the protonation state to physiological  
520 pH (7.4), and calculate the partial atomic charges, with the force field OPLS4. Docking studies with the  
521 prepared ligands were performed using Glide (Glide V7.7), with the flexible modality of Induced-fit  
522 docking (Sherman *et al*, 2006; Friesner *et al*, 2006) with extra precision (XP), followed by a side-chain  
523 minimization step using Prime. Ligands were docked within a grid around 13 Å from the centroid of the  
524 orthosteric pocket, identified using SiteMap (Schrödinger LCC) (Halgren, 2009), generating ten poses per  
525 ligand. Docking poses were visually inspected, independently from the docking score, and those with the  
526 highest number of consistent interactions were selected for simulation.

527

### 528 **5.6.3 Molecular dynamics simulations**

529 *Pf*PolK model with the different substrates was simulated to clarify which residues contributed to the  
530 stability within the binding site. Molecular Dynamics (MD) simulations were carried out using the  
531 Desmond engine (Bowers *et al*, 2006) with the OPLS4 force-field (Lu *et al*, 2021). The simulated system  
532 encompassed the protein-ligand/cofactor complex, a predefined water model (TIP3P) (Jorgensen *et al*,  
533 1983) as a solvent, counterions (Na<sup>+</sup> or Cl<sup>-</sup> adjusted to neutralize the overall system charge) and a POPC  
534 membrane based in the transmembrane motifs determined in the model. The system was treated in an  
535 orthorhombic box with periodic boundary conditions specifying the shape and the size of the box as  
536 10x10x10 Å distance from the box edges to any atom of the protein. Short-range coulombic interactions  
537 were performed using time steps of 1 fs and a cut-off value of 9.0 Å, whereas long-range coulombic  
538 interactions were handled using the Smooth Particle Mesh Ewald (PME) method (Darden *et al*, 1993).  
539 PolK+GTP+substrates systems were then subjected to simulations of 100 ns for equilibration purposes,  
540 from which the last frame was used to generate new replicas. The equilibrated system underwent at least 1  
541 μs production simulation, in four-five replicas (total of 5 μs per substrate), followed by analysis to  
542 characterize the protein-ligand interaction. The results of the simulations, in the form of trajectory and  
543 interaction data, are available on the Zenodo repository (code: 10.5281/zenodo.7540985). MD trajectories

544 were visualized, and figures were produced using PyMOL v.2.5.2 (Schrödinger LCC, New York, NY,  
545 USA).  
546 Protein-ligand interactions and distances were determined using the Simulation Event Analysis pipeline  
547 implemented using the software Maestro 2022v.4 (Schrödinger LCC). The compounds' binding energy  
548 was calculated using the Born and surface area continuum solvation (MM/GBSA) model, using Prime  
549 (Jacobson *et al*, 2004) and the implemented thermal MM/GBSA script. For the calculations, each 10<sup>th</sup> frame  
550 of MD was used. Finally, root mean square deviation (RMSD) values of the protein backbone were used to  
551 monitor simulation equilibration and protein changes (supporting information Figure S1). The fluctuation  
552 (RMSF) by residues was calculated using the initial MD frame as a reference and compared between ligand-  
553 bound and apostructure simulations (supporting information Figure S2).

554

### 555 **5.7 Generation of conditional $\Delta$ -*polk* parasites**

556 A single guide RNA (sgRNA) targeting the PolK genomic locus in PfNF54 strain (PfNF54\_070015200)  
557 was designed with the CHOPCHOP gRNA Design Tool (Labun *et al*, 2019). To generate the plasmid  
558 expressing the *Streptococcus pyogenes* Cas9 and the sgRNA, the primers 5'-  
559 AAGTATATAATATTGGACATAGAACAATGTCACAAGTTTTAGAGCTAGAA-3' and 5'-  
560 TTCTAGCTCTAAAACCTTGACATTGTTCTATGTCCAATATTATATACTT-3' were annealed and  
561 ligated into a BbsI-digested pDC2-Cas9-hDHFryFCU plasmid (a gift from Ellen Knuepfer) (Knuepfer *et*  
562 *al*, 2017). The donor plasmid, a pUC19 plasmid containing the recodonized PfNF54\_070015200 gene, was  
563 manufactured by GenWiz Gene Synthesis (Azenta, Chelmsford, USA) with the coding sequence for a  
564 3xHA (Human influenza hemagglutinin) tag in the N-terminal part of the PolK. In addition, this sequence  
565 was flanked with two loxP sequences and two homology regions of 500 bp corresponding to intergenic  
566 regions upstream and downstream of PfNF54\_070015200. Confirmation of the appropriate modification of  
567 the PolK gene after transfection was assessed by diagnostic PCR using primers that specifically recognized  
568 the wild-type sequence (PolK-WT-forward: 5'-GGATATAGGAGAGGTTTGCCAC-3' and PolK-WT-  
569 reverse: 5'-CCTACTATTGCCGCCATTG-3') or the recodonized sequence (PolK-recod-forward: 5'-  
570 GCTTCGTATTGTTTCGTGATA-3' and PolK-recod-reverse: 5'-CCACCGAACAACTCTAAGAA-3').  
571 Subsequent limiting dilution was performed to generate clones of PolK locus-modified parasites resulting  
572 in the isolation of PolK-loxP-C3, PolK-loxP-E3 and PolK-loxP-G9 clones, in which the modification of  
573 the locus was reconfirmed again by PCR. Efficiency of the conditional excision of the floxed PolK-loxP  
574 clones was assessed by the addition of 50 nM rapamycin or dimethyl sulfoxide (DMSO; vehicle control)  
575 in ring-stage synchronized cultures. Cells were treated for 24 h, followed by washing and incubation for

576 another 24 h to allow parasite maturation. To demonstrate the efficient excision of PolK-loxP, gDNA from  
577 the clones were obtained and used in diagnostic PCR with primers annealing in the homology regions PolK-  
578 HR1-forward (5'-ATGATATTTACCATAATTTATGGGC-3') and PolK-HR2-reverse (5'-  
579 CTGTTTTTCTCTTTATTCCTTCTC-3'). The three clones were used in all subsequent experiments.

580

## 581 **5.8 Immunofluorescence assays**

582 Before the immunofluorescence assays (IFA) procedure,  $\mu$ -Slide eight-well chamber slides (Ibidi GmbH,  
583 Gräfelfing, Germany) were incubated in a working poly-L-lysine solution (1:10 dilution from stock 0.1%)  
584 for 5 minutes at RT. The poly-L-lysine was then removed with suction and the slides were left to dry. In  
585 parallel, parasite cultures were washed 3 times with RPMI medium and 150  $\mu$ L of culture were placed in  
586 the pre-treated slide. The cultures were then fixed by adding 150  $\mu$ L of paraformaldehyde 4% in PBS to the  
587 slides and incubating them at 37 °C for 30 minutes. After washing the cultures once with PBS, the cultures  
588 were permeabilized by adding 150  $\mu$ L of 0.1% Triton-X-100 in PBS and incubating them at room  
589 temperature for 15 minutes. The cultures were then washed 3 times with PBS, and were blocked by adding  
590 150  $\mu$ L of 3% BSA in PBS and incubating them for 30 minutes at room temperature at 400 rpm, orbital  
591 agitation. The cultures were then washed 3 times with PBS and 150  $\mu$ L of primary antibody solution (Rabbit  
592 polyclonal anti-ferredoxin-NADP reductase, diluted 1:100 and Rat Anti-HA, diluted 1:20 in 0.75%  
593 BSA/PBS) was then added, and the cultures were incubated overnight at 4°C with at 400 rpm. Afterwards,  
594 the cells were washed 3 times with PBS to remove the excess primary antibody solution. The supernatant  
595 was removed and secondary antibody solution (Goat anti-Rabbit IgG (H+L) Alexa Fluor 488, #A11034,  
596 (Life Technologies, Carlsbad, California, EUA) and Goat anti-Rat IgG (H&L) - AlexaFluor™ 594,  
597 #A11007 (Invitrogen, Waltham, Massachusetts, EUA), diluted 1:100 in 0.75% BSA/PBS, was added to the  
598 cultures and incubated for 1 hour at room temperature at 400 rpm, orbital agitation. Hoechst (Thermo Fisher  
599 Scientific, Waltham, Massachusetts, EUA) was diluted 1:1000 in the mix and also added to cultures. The  
600 cells were then washed 3 times with PBS to remove excess secondary antibody. The supernatant was  
601 removed and the slides maintained in 150  $\mu$ L of PBS. For microscopy analysis, an Olympus IX51 inverted  
602 system microscope, equipped with an IX2-SFR X-Y stage, a U-TVIX-2 camera, and a fluorescence mirror  
603 unit cassette for UV/blue/green excitation and detection was employed.

604

## 605 **5.9 Western blot**

606 Cultures with 5% parasitaemia at trophozoite/schizont stages were centrifuged in a 15 mL tubes,  
607 resuspended in 2 volumes of 0.2% saponin in PBS and incubated on ice for 10 min. Then, 10 mL of PBS

608 was added to each sample and the mixture was centrifuged at 1800 x g for 8 min at 4 °C. The supernatants  
609 were removed and the saponin treatment was repeated two more times. The pellets were transferred to a  
610 1.5 mL vial and washed with PBS, then resuspended in 100 µL of lysis buffer. BioRad Bradford Assay was  
611 carried out and 10 µg of each sample was applied in SDS-PAGE gels and then transferred to a PVDF  
612 membrane (Bio-Rad, 0.45 µm pore size) by electro-transfer (30 V constant overnight) in the Mini Trans-  
613 Blot cell module (Bio-Rad). The membrane was blocked for 1 h at 4 °C with 3% (w/v) BSA in PBS-T (10  
614 mM Tris-HCl pH 8.0, 0.05% Tween 20) and then incubated for 1 h with a rat anti-HA primary antibody  
615 (1:500 [vol/vol] in PBS-T) for HA-detection. After three washing steps PBS-T, a secondary goat anti-rat  
616 IgG antibody, HRP conjugated, was used at 1:1000 and incubated for 1 hour. Following three washing  
617 steps, the membrane is developed with a chemiluminescent substrate (Super Signal™ West Pico PLUS)  
618 and visualized in ImageQuant LAS 4000 mini Biomolecular Imager (GE Healthcare).

619

#### 620 **5.10 Recombinant expression in yeast**

621 Heterologous expression of *PfPolK* was performed in *Saccharomyces cerevisiae* W303-1A strain. Cells  
622 were routinely cultured in liquid or solid YPD medium (2% dextrose, 2% peptone, 1% yeast extract) or  
623 liquid/solid Synthetic Defined medium (SD) without the addition of uracil and with 2% dextrose (Bergman,  
624 2001). Yeasts were transformed with either the empty vector (p416-GPD) or with p416-GPD-  
625 PfNF54\_070015200 (hereafter referred to as p416-*PfPolK*, i.e., cloned with the *Plasmodium PfPolK* gene  
626 optimized by Genscript for expression in yeast). Yeast expression vectors were transformed into yeasts by  
627 the lithium acetate method (Gietz & Woods, 2002). Transformed yeasts were routinely cultured in an SD  
628 medium and collected at the early stationary phase for enzymatic assays.

629

#### 630 **5.11 Farnesol and geranylgeraniol kinase activity assays**

631 The recombinant PolK was assayed following the method of Valentin *et al.*, for phytol kinase assays  
632 (Valentin *et al.*, 2006). For this, yeast crude extracts transformed with p416-*PfPolK* or the empty vector  
633 (control) were employed. Yeasts were cultivated until the stationary phase in SD plus dextrose medium and  
634 then cells were disrupted by glass beads (0.5 mm Ø) (Avramia & Amariei, 2022). Unbroken cells were  
635 discarded by centrifugation at 900 x g for 1 min and protein was adjusted to 50 mg/ml with 100 mM  
636 Tris/HCl pH 7.4. The reaction was performed in 1.5 mL microtubes by incubating approximately 40 mg of  
637 yeast protein with 4 mM MgCl<sub>2</sub>, 800 µM CTP, 10 mM sodium orthovanadate, 0.05% CHAPS and 2 µCi  
638 [<sup>3</sup>H] FOH or [<sup>3</sup>H] GGOH. [<sup>3</sup>H] prenol was vacuum-dried as it is commercially distributed in ethanol. The  
639 volume was adjusted to 100 µL with 100 mM Tris/HCl pH 7.4 and the reaction was initiated by adding the

640 yeast extract. In some assays, drugs were also added to the reaction or the addition of CTP was omitted as  
641 controls. After 30 min of incubation at 37 °C, the reaction was stopped by adding 500 µL of n-butanol  
642 saturated in water. The mixture was vortexed, and centrifuged at 12.000 x g for 10 min and the organic  
643 phase was dried under vacuum. The residue was suspended in 10 µL of n-butanol saturated in water and  
644 chromatographed on silica 60 plates (20x20 cm, Merck). Plates were developed for 7-10 cm with isopropyl  
645 alcohol/ammonia (32%)/water (6:3:1 by volume). FOH / GGOH standards and the respective phosphates  
646 and pyrophosphates were run on the same plate to identify the reaction products and substrates. Standards  
647 were visualized with iodine vapor. Finally, the plates were treated with EN3HANCE (Perkin Elmer) and  
648 exposed to autoradiography for several days at -70°C. The contrast and brightness of autoradiography  
649 scans was adjusted for clarity.

650

651 **Author Contributions:** MC and IBV contributed to conceptualization, formal analysis, investigation,  
652 methodology and writing. AH, TK, AF, MPA, MR, contributed to the investigation, methodology, and  
653 formal analysis. AMK, LI, TK and AH also contributed to writing – review & editing.  
654 AMK and LI also contributed to project administration, funding acquisition, supervision. TK also  
655 contributed to data analyses from the bioinformatics and molecular modelling parts.

656

657 **Funding:** MC and IBV are fellows from the *Fundação de Amparo à Pesquisa do Estado de São Paulo*  
658 (FAPESP); MC FAPESP process numbers: 2020/14897-6 and 2018/02924-9; IBV FAPESP process  
659 number: 2019/13419-6. This work was supported by FAPESP process number: 2017/22452-1 and  
660 2014/10443-0, awarded to AMK and AHL respectively, *Coordenação de Aperfeiçoamento de Pessoal de*  
661 *Nível Superior (CAPES)* and *Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)*.  
662 ISGlobal is a member of the CERCA Program, Generalitat de Catalunya. ISGlobal as Severo Ochoa center  
663 of excellence. Ramon Areces supports ISGlobal Malaria Program. LI receives support by PID2019-  
664 110810RB-I00/AEI/10.13039/501100011033 grant from the Spanish Ministry of Science & Innovation.  
665 MPA is supported by a FI Fellowship from the Generalitat de Catalunya supported by *Secretaria*  
666 *d'Universitats i Recerca de la Generalitat de Catalunya* and *Fons Social Europeu* (2021 FI\_B 00470) and  
667 AF is supported by a FPU Fellowship from the Spanish Ministry of Universities (FPU20-04484). TK is  
668 funded by the CIMF and TüCAD2. CIMF and TüCAD2 are funded by the Federal Ministry of Education  
669 and Research (BMBF) and the Baden-Württemberg Ministry of Science as part of the Excellence Strategy  
670 of the German Federal and State Governments.

671

672 **Acknowledgments:** We thank Prof. Moritz Treeck (The Francis Crick Institute, London, United Kingdom)  
673 for providing the Cre-LoxP *P. falciparum* NF54 strain, and Prof. Xavier Fernández-Busquets and Yunuen  
674 Avalos Padilla for providing the anti-ferredoxin-NADP reductase antibody and help in IFA experiments.  
675 We also thank the Blood Center of Sírío Libanês Hospital (São Paulo, Brazil), for the gift of erythrocytes  
676 and the CSC-Finland for the generous computational resources.

677

678 **Conflicts of Interest:** The authors declare that they have no competing interests.

679

680

## REFERENCES

- 681 Avramia, I., & Amariei, S. (2022). A simple and efficient mechanical cell disruption method using glass  
682 beads to extract  $\beta$ -glucans from spent brewer's yeast. *Applied Sciences*, 12(2), 648.
- 683 Bansal, V. S., & Vaidya, S. (1994). Characterization of 2 Distinct Alkyl Pyrophosphatase Activities from  
684 Rat-Liver Microsomes. *Archives of biochemistry and biophysics*, 315(2), 393-399.
- 685 Bentinger, M., Grünler, J., Peterson, E., Swiezewska, E., & Dallner, G. (1998). Phosphorylation of farnesol  
686 in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase. *Archives of*  
687 *biochemistry and biophysics*, 353(2), 191-198.
- 688 Bergman, L. W. (2001). Growth and maintenance of yeast. In *Two-hybrid systems* (pp. 9-14). Humana  
689 Press.
- 690 Bloland, P. B., & World Health Organization. (2001) *Drug resistance in malaria*. Geneva: World Health  
691 Organization.
- 692 Boucher, M. J., Ghosh, S., Zhang, L., Lal, A., Jang, S. W., Ju, A., ... & Yeh, E. (2018). Integrative  
693 proteomics and bioinformatic prediction enable a high-confidence apicoplast proteome in malaria  
694 parasites. *PLoS biology*, 16(9), e2005895.
- 695 Bowers, K.J.; Sacerdoti, F.D.; Salmon, J.K.; Shan, Y.; Shaw, D.E.; Chow, E.; Xu, H.; Dror, R.O.;  
696 Eastwood, M.P.; Gregersen, B.A.; *et al.* Molecular Dynamics---Scalable Algorithms for Molecular  
697 Dynamics Simulations on Commodity Clusters. In Proceedings of the Proceedings of the 2006  
698 ACM/IEEE conference on Supercomputing - SC '06; ACM Press: New York, New York, USA,  
699 2006; p. 84.
- 700 Brown, A. C., & Parish, T. (2008). Dxr is essential in Mycobacterium tuberculosis and fosmidomycin  
701 resistance is due to a lack of uptake. *BMC microbiology*, 8, 1-9.

- 702 Buesing, N., & Gessner, M. (2003). Incorporation of Radiolabeled Leucine into Protein to Estimate  
703 Bacterial Production in Plant Litter, Sediment, Epiphytic Biofilms, and Water Samples. *Microbial*  
704 *Ecology*, 45(3), 291–301.
- 705 Bushell, E., Gomes, A. R., Sanderson, T., Anar, B., Girling, G., Herd, C., Metcalf, T., Modrzynska, K.,  
706 Schwach, F., Martin, R. E., Mather, M. W., McFadden, G. I., Parts, L., Rutledge, G. G., Vaidya, A. B.,  
707 Wengelnik, K., Rayner, J. C., & Billker, O. (2017). Functional Profiling of a Plasmodium Genome  
708 Reveals an Abundance of Essential Genes. *Cell*, 170(2), 260–272.e8.
- 709 Cassera, M. B., Gozzo, F. C., D'Alexandri, F. L., Merino, E. F., del Portillo, H. A., Peres, V. J., Almeida,  
710 I. C., Eberlin, M. N., Wunderlich, G., Wiesner, J., Jomaa, H., Kimura, E. A., & Katzin, A. M. (2004).  
711 The methylerythritol phosphate pathway is functionally active in all intraerythrocytic stages of  
712 *Plasmodium falciparum*. *The Journal of Biological Chemistry*, 279(50), 51749–51759.
- 713 Cassera, M. B., Gozzo, F. C., D'Alexandri, F. L., methylerythritol phosphate pathway is functionally active  
714 in all intraerythrocytic stages of *Plasmodium falciparum*. *J Biol Chem* 279, 51749-51759.
- 715 Chappell, L., Ross, P., Orchard, L., Russell, T. J., Otto, T. D., Berriman, M., ... & Llinás, M. (2020).  
716 Refining the transcriptome of the human malaria parasite *Plasmodium falciparum* using amplification-  
717 free RNA-seq. *BMC genomics*, 21, 1-19.
- 718 Christophers, S. R., & Fulton, J. D. (1939). Experiments with isolated malaria parasites (*Plasmodium*  
719 *knowlesi*) free from red cells. *Annals of Tropical Medicine & Parasitology*, 33(2), 161-170.
- 720 Crispim, M., Verdager, I. B., Silva, S. F., & Katzin, A. M. (2022). Suitability of methods for *Plasmodium*  
721 *falciparum* cultivation in atmospheric air. *Memórias do Instituto Oswaldo Cruz*, 117.
- 722 Darden, T.; York, D.; Pedersen, L. Particle Mesh Ewald: An  $N \cdot \log(N)$  Method for Ewald Sums in  
723 Large Systems. *The Journal of Chemical Physics* 1993, 98, 10089–10092, doi:10.1063/1.464397.
- 724 Darriba D, Taboada GL, Doallo R, Posada D. ProtTest 3: fast selection of best-fit models of protein  
725 evolution. *Bioinformatics*. 2011 Apr 15;27(8):1164–5.
- 726 de Macedo, C. S., Uhrig, M. L., Kimura, E. A., & Katzin, A. M. (2002). Characterization of the isoprenoid  
727 chain of coenzyme Q in *Plasmodium falciparum*. *FEMS Microbiology Letters*, 207(1), 13-20.
- 728 de Wolf, E., Abdullah, M. I., Jones, S. M., Menezes, K., Moss, D. M., Drijfhout, F. P., ... & Richardson, A.  
729 (2017). Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-  
730 resistant ovarian cancer. *Scientific reports*, 7(1), 5410.
- 731 Dinesh, N.; Pallerla, D.S.; Kaur, P.K.; Kishore Babu, N.; Singh, S. *Leishmania donovani* 3-hydroxy-3-  
732 methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical  
733 and inhibition studies. *Microb. Pathog.* **2014**, 66, 14–23.

- 734 Edgar RC. MUSCLE: a multiple sequence alignment method with reduced time and space complexity.  
735 BMC Bioinformatics. 2004 Aug 19;5:113.
- 736 Elsabrouty, R., Jo, Y., Hwang, S., Jun, D. J., & DeBose-Boyd, R. A. (2021). Type 1 polyisoprenoid  
737 diphosphate phosphatase modulates geranylgeranyl-mediated control of HMG CoA reductase and  
738 UBIAD1. *Elife*, *10*, e64688.
- 739 Farnsworth, C. C., Casey, P. J., Howald, W. N., Glomset, J. A., & Gelb, M. H. (1990). Structural  
740 characterization of prenyl groups attached to proteins. *Methods*, *1*(3), 231-240.
- 741 Fenollar, À., Ros-Lucas, A., Alberione, M. P., Martínez-Peinado, N., Ramírez, M., Rosales-Motos, M. Á.,  
742 ... & Izquierdo, L. (2022). Compounds targeting GPI biosynthesis or N-glycosylation are active against  
743 *Plasmodium falciparum*. *Computational and Structural Biotechnology Journal*, *20*, 850-863.
- 744 Fernandes, J. F., Lell, B., Agnandji, S. T., Obiang, R. M., Bassat, Q., Kremsner, P. G., ... & Grobusch, M.  
745 P. (2015). Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials. *Future*  
746 *Microbiology*, *10*(8), 1375-1390.
- 747 Fitzpatrick, A. H., Bhandari, J., & Crowell, D. N. (2011). Farnesol kinase is involved in farnesol  
748 metabolism, ABA signaling and flower development in Arabidopsis. *The Plant Journal*, *66*(6), 1078-  
749 1088.
- 750 Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin,  
751 P.C.; Mainz, D.T. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic  
752 Enclosure for Protein–Ligand Complexes
- 753 Gietz, R. D., & Woods, R. A. (2002). Transformation of yeast by lithium acetate/single-stranded carrier  
754 DNA/polyethylene glycol method. *Methods in enzymology*, *350*, 87-96.
- 755 Gowda, D. C., & Davidson, E. A. (1999). Protein glycosylation in the malaria parasite. *Parasitology*  
756 *today*, *15*(4), 147-152.
- 757 Guggisberg, A. M., Amthor, R. E., & Odom, A. R. (2014). Isoprenoid biosynthesis in *Plasmodium*  
758 *falciparum*. *Eukaryotic cell*, *13*(11), 1348-1359.
- 759 Guggisberg, A. M., Sundararaman, S. A., Lanaspá, M., Moraleda, C., González, R., Mayor, A., ... & Odom,  
760 A. R. (2016). Whole-genome sequencing to evaluate the resistance landscape following antimalarial  
761 treatment failure with fosmidomycin-clindamycin. *The Journal of infectious diseases*, *214*(7), 1085-  
762 1091.
- 763 Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods  
764 to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Syst Biol*.  
765 2010 May;59(3):307–21.

- 766 Halgren, T.A. Identifying and Characterizing Binding Sites and Assessing Druggability. *J. Chem. Inf.*  
767 *Model.* 2009, 49, 377–389, doi:10.1021/ci800324m.
- 768 Hartley, M. D., & Imperiali, B. (2012). At the membrane frontier: a prospectus on the remarkable  
769 evolutionary conservation of polyprenolprenols and polyprenyl-phosphates. *Archives of biochemistry*  
770 *and biophysics*, 517(2), 83-97.
- 771 Healy, F.M.; Prior, I.A.; MacEwan, D.J. The importance of Ras in drug resistance in cancer. *Br. J.*  
772 *Pharmacol.* **2022**, 179, 2844–2867.
- 773 Howe, R., Kelly, M., Jimah, J., Hodge, D., & Odom, A. R. (2013). Isoprenoid biosynthesis inhibition  
774 disrupts Rab5 localization and food vacuolar integrity in *Plasmodium falciparum*. *Eukaryotic*  
775 *cell*, 12(2), 215-223.
- 776 Huang Y, Niu B, Gao Y, Fu L, Li W. CD-HIT Suite: a web server for clustering and comparing  
777 biological sequences. *Bioinformatics*. 2010 Mar 1;26(5):680–2.
- 778 Ischebeck, T., Zbierzak, A. M., Kanwischer, M., & Dörmann, P. (2006). A salvage pathway for phytol  
779 metabolism in Arabidopsis. *Journal of Biological Chemistry*, 281(5), 2470-2477.
- 780 Jacobson, M.P.; Pincus, D.L.; Rapp, C.S.; Day, T.J.F.; Honig, B.; Shaw, D.E.; Friesner, R.A. A  
781 Hierarchical Approach to All-Atom Protein Loop Prediction. *PROTEINS* 2004, 55, 351–367,  
782 doi:10.1002/prot.10613.
- 783 Janouskovec, J., Horak, A., Obornik, M., Lukes, J., and Keeling, P. J. (2010) A common red algal origin  
784 of the apicomplexan, dinoflagellate, and heterokont plastids. *Proc Natl Acad Sci U S A* 107, 10949-  
785 10954.
- 786 Jawad, M. J., Ibrahim, S., Kumar, M., Burgert, C., Li, W. W., & Richardson, A. (2022). Identification of  
787 foods that affect the anti-cancer activity of pitavastatin in cells. *Oncology Letters*, 23(3), 1-8.
- 788 Jordão, F. M., Kimura, E. A., & Katzin, A. M. (2011) Isoprenoid biosynthesis in the erythrocytic stages of  
789 *Plasmodium falciparum*. *Memorias do Instituto Oswaldo Cruz* 106, 134-141.
- 790 Jorgensen, W.L.; Chandrasekhar, J.; Madura, J.D.; Impey, R.W.; Klein, M.L. Comparison of Simple  
791 Potential Functions for Simulating Liquid Water. *The Journal of Chemical Physics* 1983, 79, 926–  
792 935, doi:10.1063/1.445869.
- 793 Kennedy, K., Cobbold, S. A., Hanssen, E., Birnbaum, J., Spillman, N. J., McHugh, E., ... & Ralph, S. A.  
794 (2019). Delayed death in the malaria parasite *Plasmodium falciparum* is caused by disruption of  
795 prenylation-dependent intracellular trafficking. *PLoS Biology*, 17(7), e3000376.

- 796 Kimura, E. A., Wunderlich, G., Jordão, F. M., Tonhosolo, R., Gabriel, H. B., Sussmann, R. A., ... & Katzin,  
797 A. M. (2011). *Use of radioactive precursors for biochemical characterization the biosynthesis of*  
798 *isoprenoids in intraerythrocytic stages of Plasmodium falciparum* (pp. 27-46). IntechOpen.
- 799 Knuepfer, E., Napiorkowska, M., Van Ooij, C., & Holder, A. A. (2017). Generating conditional gene  
800 knockouts in Plasmodium—a toolkit to produce stable DiCre recombinase-expressing parasite lines  
801 using CRISPR/Cas9. *Scientific reports*, 7(1), 1-12.
- 802 Köhler, S., Delwiche, C. F., Denny, P. W., Tilney, L. G., Webster, P., Wilson, R. J. M., ... & Roos, D. S.  
803 (1997). A plastid of probable green algal origin in Apicomplexan parasites. *Science*, 275(5305), 1485-  
804 1489.
- 805 Labun, K., Montague, T. G., Krause, M., Torres Cleuren, Y. N., Tjeldnes, H., & Valen, E. (2019).  
806 CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. *Nucleic acids*  
807 *research*, 47(W1), W171-W174.
- 808 Lambros, C., and Vanderberg, J. P. (1979) Synchronization of *Plasmodium falciparum* erythrocytic stages  
809 in culture. *Journal of Parasitology* 65, 418-420.
- 810 Lanaspa, M., Moraleda, C., Machevo, S., González, R., Serrano, B., Macete, E., ... & Bassat, Q. (2012).  
811 Inadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican  
812 children less than three years old with uncomplicated *Plasmodium falciparum* malaria. *Antimicrobial*  
813 *agents and chemotherapy*, 56(6), 2923-2928.
- 814 Lell, B., Ruangweerayut, R., Wiesner, J., Missinou, M. A., Schindler, A., Baranek, T., ... & Kremsner, P.  
815 G. (2003). Fosmidomycin, a novel chemotherapeutic agent for malaria. *Antimicrobial agents and*  
816 *chemotherapy*, 47(2), 735-738.
- 817 Lu, C.; Wu, C.; Ghoreishi, D.; Chen, W.; Wang, L.; Damm, W.; Ross, G.A.; Dahlgren, M.K.; Russell, E.;  
818 Von Bargen, C.D.; *et al.* OPLS4: Improving Force Field Accuracy on Challenging Regimes of  
819 Chemical Space. *J Chem Theory Comput* 2021, 17, 4291–4300, doi:10.1021/acs.jctc.1c00302.
- 820 Martin, R. E., & Kirk, K. (2007). Transport of the essential nutrient isoleucine in human erythrocytes  
821 infected with the malaria parasite *Plasmodium falciparum*. *Blood*, 109(5), 2217-2224.
- 822 Mombo-Ngoma, G., Remppis, J., Sievers, M., Zoleko Manego, R., Endamne, L., Kabwende, L., ... &  
823 Kremsner, P. G. (2018). Efficacy and safety of fosmidomycin–piperaquine as nonartemisinin-based  
824 combination therapy for uncomplicated falciparum malaria: A single-arm, age de-escalation proof-of-  
825 concept study in Gabon. *Clinical Infectious Diseases*, 66(12), 1823-1830.
- 826 Nair, S. C., Brooks, C. F., Goodman, C. D., Sturm, A., McFadden, G. I., Sundriyal, S., Anglin, J. L.,  
827 Song, Y., Moreno, S. N., & Striepen, B. (2011). Apicoplast isoprenoid precursor synthesis and the

- 828 molecular basis of fosmidomycin resistance in *Toxoplasma gondii*. *The Journal of experimental*  
829 *medicine*, 208(7), 1547–1559. <https://doi.org/10.1084/jem.20110039>
- 830 Nakatani, Y., Ribeiro, N., Streiff, S., Gotoh, M., Pozzi, G., Désaubry, L., & Milon, A. (2014). Search for  
831 the most ‘primitive’ membranes and their reinforcers: a review of the polyprenyl phosphates  
832 theory. *Origins of Life and Evolution of Biospheres*, 44, 197-208.
- 833 Ohnuma, S. I., Watanabe, M., & Nishino, T. (1996). Identification and characterization of geranylgeraniol  
834 kinase and geranylgeranyl phosphate kinase from the Archaeobacterium *Sulfolobus acidocaldarius*. *The*  
835 *Journal of Biochemistry*, 119(3), 541-547.
- 836 Ohnuma, S., Watanabe, M., & Nishino, T. (1996). Identification and characterization of geranylgeraniol  
837 kinase and geranylgeranyl phosphate kinase from the Archaeobacterium *Sulfolobus*  
838 *acidocaldarius*. *Journal of biochemistry*, 119(3), 541–547.  
839 <https://doi.org/10.1093/oxfordjournals.jbchem.a021275>
- 840 Okada, M., Rajaram, K., Swift, R. P., Mixon, A., Maschek, J. A., Prigge, S. T., & Sigala, P. A. (2022).  
841 Critical role for isoprenoids in apicoplast biogenesis by malaria parasites. *Elife*, 11, e73208.
- 842 Popjak, G., Edmond, J., Clifford, K., & Williams, V. I. N. C. E. N. T. (1969). Biosynthesis and structure of  
843 a new intermediate between farnesyl pyrophosphate and squalene. *Journal of Biological*  
844 *Chemistry*, 244(7), 1897-1918.
- 845 Portugaliza, H. P., Llorà-Batlle, O., Rosanas-Urgell, A., & Cortés, A. (2019). Reporter lines based on the  
846 *gexp02* promoter enable early quantification of sexual conversion rates in the malaria parasite  
847 *Plasmodium falciparum*. *Scientific reports*, 9(1), 1-12.
- 848 Prior, I.A.; Lewis, P.D.; Mattos, C. A comprehensive survey of Ras mutations in cancer. *Cancer*  
849 *Res.* **2012**, 72, 2457–2467.
- 850 Radfar, A., Mendez, D., Moneriz, C., Linares, M., Marin-Garcia, P., Puyet, A., Diez, A., and Bautista, J.  
851 M. (2009) Synchronous culture of *Plasmodium falciparum* at high parasitemia levels. *Nature protocols*  
852 4, 1899-1915.
- 853 Rovira-Graells, N., Aguilera-Simón, S., Tinto-Font, E., & Cortés, A. (2016). New assays to characterise  
854 growth-related phenotypes of *Plasmodium falciparum* reveal variation in density-dependent growth  
855 inhibition between parasite lines. *PLoS One*, 11(10), e0165358.
- 856 Rowe, J. A., Scragg, I. G., Kwiatkowski, D., Ferguson, D. J., Carucci, D. J., and Newbold, C. I. (1998)  
857 Implications of mycoplasma contamination in *Plasmodium falciparum* cultures and methods for its  
858 detection and eradication. *Mol Biochem Parasitol* 92, 177-180


- 859 Seeber, F., and Soldati-Favre, D. (2010) Metabolic pathways in the apicoplast of apicomplexa. *Int Rev Cell*  
860 *Mol Biol* 281, 161-228.
- 861 Sherman, W.; Day, T.; Jacobson, M.P.; Friesner, R.A.; Farid, R. Novel Procedure for Modeling  
862 Ligand/Receptor Induced Fit Effects. *J. Med. Chem.* 2006, 49, 534–553, doi:10.1021/jm050540c.
- 863 Smilkstein, M., Sriwilaijaroen, N., Kelly, J. X., Wilairat, P., & Riscoe, M. (2004) Simple and inexpensive  
864 fluorescence-based technique for high-throughput antimalarial drug screening. *Antimicrobial agents*  
865 *and chemotherapy* 48, 1803-1806.
- 866 Suazo, K. F., Schaber, C., Palsuledesai, C. C., Odom John, A. R., & Distefano, M. D. (2016). Global  
867 proteomic analysis of prenylated proteins in *Plasmodium falciparum* using an alkyne-modified  
868 isoprenoid analogue. *Scientific reports*, 6(1), 38615.
- 869 Swift, R. P., Rajaram, K., Liu, H. B., & Prigge, S. T. (2021). Dephospho-CoA kinase, a nuclear-encoded  
870 apicoplast protein, remains active and essential after *Plasmodium falciparum* apicoplast disruption. *The*  
871 *EMBO journal*, 40(16), e107247.
- 872 Tibúrcio, M., Yang, A. S., Yahata, K., Suárez-Cortés, P., Belda, H., Baumgarten, S., ... & Treeck, M.  
873 (2019). A novel tool for the generation of conditional knockouts to study gene function across the  
874 *Plasmodium falciparum* life cycle. *MBio*, 10(5), e01170-19.
- 875 Thumuluri, V., Almagro Armenteros, J. J., Johansen, A. R., Nielsen, H., & Winther, O. (2022). DeepLoc  
876 2.0: multi-label subcellular localization prediction using protein language models. *Nucleic acids*  
877 *research*, 50(W1), W228–W234.
- 878 Trager, W., and Jensen, J. B. (1976) Human malaria parasites in continuous culture. *Science* 193, 673-675.
- 879 Valentin, H. E., Lincoln, K., Moshiri, F., Jensen, P. K., Qi, Q., Venkatesh, T. V., ... & Last, R. L. (2006).  
880 The Arabidopsis vitamin E pathway gene5-1 mutant reveals a critical role for phytol kinase in seed  
881 tocopherol biosynthesis. *The Plant Cell*, 18(1), 212-224.
- 882 Verdaguer, I. B., Crispim, M., Hernández, A., & Katzin, A. M. (2022). The Biomedical Importance of the  
883 Missing Pathway for Farnesol and Geranylgeraniol Salvage. *Molecules*, 27(24), 8691.
- 884 Verdaguer, I. B., Crispim, M., Zafra, C. A., Sussmann, R. A. C., Buriticá, N. L., Melo, H. R., ... & Katzin,  
885 A. M. (2021). Exploring ubiquinone biosynthesis inhibition as a strategy for improving atovaquone  
886 efficacy in malaria. *Antimicrobial Agents and Chemotherapy*, 65(4), e01516-20.
- 887 Verdaguer, I. B., Crispim, M., Zafra, C. A., Sussmann, R. A. C., Buriticá, N. L., Melo, H. R., ... & Katzin,  
888 A. M. (2021). Exploring ubiquinone biosynthesis inhibition as a strategy for improving atovaquone  
889 efficacy in malaria. *Antimicrobial Agents and Chemotherapy*, 65(4), e01516-20.

- 890 Verdaguer, I. B., Sussmann, R. A., Santiago, V. F., Palmisano, G., Moura, G. C., Mesquita, J. T., ... &  
891 Crispim, M. (2022). Isoprenoid alcohols utilization by malaria parasites. *Frontiers in Chemistry*, *10*,  
892 1035548-1035548.
- 893 Verdaguer, I. B., Zafra, C. A., Crispim, M., Sussmann, R. A., Kimura, E. A., & Katzin, A. M. (2019).  
894 Prenylquinones in human parasitic protozoa: Biosynthesis, physiological functions, and potential as  
895 chemotherapeutic targets. *Molecules*, *24*(20), 3721.
- 896 Vom Dorp, K., Hölzl, G., Plohmann, C., Eisenhut, M., Abraham, M., Weber, A. P., ... & Dörmann, P.  
897 (2015). Remobilization of phytol from chlorophyll degradation is essential for tocopherol synthesis and  
898 growth of *Arabidopsis*. *The Plant Cell*, *27*(10), 2846-2859.
- 899 Wang S, Li M, Luo X, *et al.* Inhibitory Effects of Fosmidomycin Against *Babesia microti* *in vitro*. *Front*  
900 *Cell Dev Biol.* 2020;8:247. Published 2020 Apr 28. doi:10.3389/fcell.2020.00247
- 901 World Health Organization, World malaria report 2022, WHO. (2022).
- 902 Wu, W., Herrera, Z., Ebert, D., Baska, K., Cho, S. H., DeRisi, J. L., & Yeh, E. (2015) A chemical rescue  
903 screen identifies a *Plasmodium falciparum* apicoplast inhibitor targeting MEP isoprenoid precursor  
904 biosynthesis. *Antimicrobial agents and chemotherapy* *59*, 356-364.
- 905 Yeh, E., & DeRisi, J. L. (2011) Chemical rescue of malaria parasites lacking an apicoplast defines organelle  
906 function in blood-stage *Plasmodium falciparum*. *PLoS biology* *9*, e1001138.
- 907 Zhang M, Wang C, Otto TD, *et al.* Uncovering the essential genes of the human malaria  
908 parasite *Plasmodium falciparum* by saturation mutagenesis. *Science*. 2018;360(6388):eaap7847.  
909 doi:10.1126/science.aap7847
- 910 Zhang, B., Watts, K. M., Hodge, D., Kemp, L. M., Hunstad, D. A., Hicks, L. M., & Odom, A. R. (2011) A  
911 second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic  
912 profiling. *Biochemistry* *50*, 3570-3577.
- 913 Zimbres, F. M., Valenciano, A. L., Merino, E. F., Florentin, A., Holderman, N. R., He, G., ... & Cassera,  
914 M. B. (2020). Metabolomics profiling reveals new aspects of dolichol biosynthesis in *Plasmodium*  
915 *falciparum*. *Scientific reports*, *10*(1), 1-17.
- 916
- 917
- 918

919

## SUPPORTING INFORMATION

920




921

922 **Figure S1.** A) Root mean square deviation (RMSD) values of the protein backbone were used to monitor simulation  
923 equilibration and protein changes along the trajectory time (merged 5x1  $\mu$ s). B) Root mean square fluctuation (RMSF)  
924 by residues, calculated using the initial MD frame as a reference and compared between ligand-bound, highlighting the  
925 TM2'-TM4 region (the intracellular portion) which displays a unique unfolding in the GGOH simulations.


926

927



928


929 **Figure S2. Sequence alignment.** ClustalW Multiple alignment of PolK candidate amino acid sequence, predicted in  
 930 *P. falciparum* NF54 strain against sequences with prenil kinase prediction in Uniprot database. PolK: prenil kinase,  
 931 PhyK: phytol kinase, FolK: farnesol kinase. PfPolK (*P. falciparum* NF54, D0VEH1), SsPhyK (*Synechocystis* sp.,  
 932 P74653), GmPhyK (*Glycine max*, Q2N2K1), ZmPhyK (*Zea mays*, Q2N2K4), OsPhyK (*Oryza sativa*, Q7XR51),  
 933 AtPhyK (*Arabidopsis thaliana*, Q9LZ76), AtFolK (*Arabidopsis thaliana*, Q67ZM7). Yellow indicates similarity and  
 934 red indicates identity.



935


936 **Figure S3. Phylogenetic analysis of the retrieved representative prenil binding proteins.** Inset of the overall  
 937 phylogenetic dendrogram of potential prenil kinases generated using maximum likelihood method (see methods).

938 Branch support values (Bayes posterior probability) are displayed as numbers for the most relevant clade separation,  
 939 as well as colours (from the highest scores, in blue, to the lowest values, in red) and thickness of the branches.  
 940 Organisms and genes from Opisthokont group and some extra outliers are highlighted.  
 941



942  
 943 **Figure S4. Phylogenetic analysis of dolichol kinase.** Inset of the overall phylogenetic dendrogram of potential prenil  
 944 kinases generated using maximum likelihood method (see methods). Branch support values (Bayes posterior  
 945 probability) are displayed as numbers for the most relevant clade separation, as well as colours (from the highest scores,  
 946 in blue, to the lowest values, in red) and thickness of the branches. Apicomplexa clades and the *C. reinhardtii*  
 947 (A0XX\_CHLRE, where A0XX is a generic label for all the *C. reinhardtii*'s taxa) are highlighted.  
 948

949



950

951 **Figure S5. Original images of Western blot analysis.** Photographs of Western blot of transgenic parasites (left) and  
952 the respective nitrocellulose membrane (right) with the protein ladder (MM). Western blot was performed to analyse  
953 the HA-tagged *PfPolK* of parasites in which *PfPolK* was excised (Lane 1, parasites exposed to rapamycin) or preserved  
954 (Lane 2, parasites exposed to DMSO). The rest of the lanes (group of lanes 3 and onwards) correspond to experiments  
955 not related to this article.